These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 15282551)

  • 21. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation.
    Kondapaka SB; Singh SS; Dasmahapatra GP; Sausville EA; Roy KK
    Mol Cancer Ther; 2003 Nov; 2(11):1093-103. PubMed ID: 14617782
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN.
    Vivanco I; Palaskas N; Tran C; Finn SP; Getz G; Kennedy NJ; Jiao J; Rose J; Xie W; Loda M; Golub T; Mellinghoff IK; Davis RJ; Wu H; Sawyers CL
    Cancer Cell; 2007 Jun; 11(6):555-69. PubMed ID: 17560336
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway.
    Zhang J; Choi Y; Mavromatis B; Lichtenstein A; Li W
    Oncogene; 2003 Sep; 22(40):6289-95. PubMed ID: 13679867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression.
    Graff JR; Konicek BW; McNulty AM; Wang Z; Houck K; Allen S; Paul JD; Hbaiu A; Goode RG; Sandusky GE; Vessella RL; Neubauer BL
    J Biol Chem; 2000 Aug; 275(32):24500-5. PubMed ID: 10827191
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells.
    Choi Y; Zhang J; Murga C; Yu H; Koller E; Monia BP; Gutkind JS; Li W
    Oncogene; 2002 Aug; 21(34):5289-300. PubMed ID: 12149650
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Indole-3-carbinol inhibits protein kinase B/Akt and induces apoptosis in the human breast tumor cell line MDA MB468 but not in the nontumorigenic HBL100 line.
    Howells LM; Gallacher-Horley B; Houghton CE; Manson MM; Hudson EA
    Mol Cancer Ther; 2002 Nov; 1(13):1161-72. PubMed ID: 12479697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Insulin-like growth factor-I inhibits transcriptional responses of transforming growth factor-beta by phosphatidylinositol 3-kinase/Akt-dependent suppression of the activation of Smad3 but not Smad2.
    Song K; Cornelius SC; Reiss M; Danielpour D
    J Biol Chem; 2003 Oct; 278(40):38342-51. PubMed ID: 12876289
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PI3K/AKT signaling and systemic autoimmunity.
    Patel RK; Mohan C
    Immunol Res; 2005; 31(1):47-55. PubMed ID: 15591622
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of phosphatidylinositol 3'-kinase induces preferentially killing of PTEN-null T leukemias through AKT pathway.
    Uddin S; Hussain A; Al-Hussein K; Platanias LC; Bhatia KG
    Biochem Biophys Res Commun; 2004 Jul; 320(3):932-8. PubMed ID: 15240138
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The protein kinase C super-family member PKN is regulated by mTOR and influences differentiation during prostate cancer progression.
    Yang CS; Melhuish TA; Spencer A; Ni L; Hao Y; Jividen K; Harris TE; Snow C; Frierson HF; Wotton D; Paschal BM
    Prostate; 2017 Nov; 77(15):1452-1467. PubMed ID: 28875501
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activation of the PI3K/Akt signal transduction pathway and increased levels of insulin receptor in protein repair-deficient mice.
    Farrar C; Houser CR; Clarke S
    Aging Cell; 2005 Feb; 4(1):1-12. PubMed ID: 15659208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate growth and tumorigenesis.
    Chesire DR; Ewing CM; Gage WR; Isaacs WB
    Oncogene; 2002 Apr; 21(17):2679-94. PubMed ID: 11965541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The interaction of PKN3 with RhoC promotes malignant growth.
    Unsal-Kacmaz K; Ragunathan S; Rosfjord E; Dann S; Upeslacis E; Grillo M; Hernandez R; Mack F; Klippel A
    Mol Oncol; 2012 Jun; 6(3):284-98. PubMed ID: 22217540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase.
    Luo J; Sobkiw CL; Logsdon NM; Watt JM; Signoretti S; O'Connell F; Shin E; Shim Y; Pao L; Neel BG; Depinho RA; Loda M; Cantley LC
    Proc Natl Acad Sci U S A; 2005 Jul; 102(29):10238-43. PubMed ID: 16006513
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.
    Yuen HF; Chan KK; Grills C; Murray JT; Platt-Higgins A; Eldin OS; O'Byrne K; Janne P; Fennell DA; Johnston PG; Rudland PS; El-Tanani M
    Clin Cancer Res; 2012 Jan; 18(2):380-91. PubMed ID: 22090358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signaling.
    Vazquez F; Sellers WR
    Biochim Biophys Acta; 2000 Feb; 1470(1):M21-35. PubMed ID: 10656987
    [No Abstract]   [Full Text] [Related]  

  • 37. PTEN tumour suppressor is linked to the cell cycle control through the retinoblastoma protein.
    Paramio JM; Navarro M; Segrelles C; Gómez-Casero E; Jorcano JL
    Oncogene; 1999 Dec; 18(52):7462-8. PubMed ID: 10602505
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms underlying PTEN regulation of vascular endothelial growth factor and angiogenesis.
    Gomez-Manzano C; Fueyo J; Jiang H; Glass TL; Lee HY; Hu M; Liu JL; Jasti SL; Liu TJ; Conrad CA; Yung WK
    Ann Neurol; 2003 Jan; 53(1):109-17. PubMed ID: 12509854
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance.
    Campbell RA; Bhat-Nakshatri P; Patel NM; Constantinidou D; Ali S; Nakshatri H
    J Biol Chem; 2001 Mar; 276(13):9817-24. PubMed ID: 11139588
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
    Ghosh PM; Malik SN; Bedolla RG; Wang Y; Mikhailova M; Prihoda TJ; Troyer DA; Kreisberg JI
    Endocr Relat Cancer; 2005 Mar; 12(1):119-34. PubMed ID: 15788644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.